Neovasc Inc. (NASDAQ:NVCN) (TSE:NVC) – Leerink Swann reduced their FY2017 EPS estimates for Neovasc in a research report issued to clients and investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst D. Antalffy now anticipates that the medical equipment provider will earn ($0.19) per share for the year, down from their previous estimate of ($0.16). Leerink Swann also issued estimates for Neovasc’s Q1 2018 earnings at $0.00 EPS, Q2 2018 earnings at $0.00 EPS, Q3 2018 earnings at $0.00 EPS, Q4 2018 earnings at $0.00 EPS, FY2018 earnings at ($0.01) EPS and FY2020 earnings at $0.14 EPS.
Several other analysts also recently weighed in on NVCN. Zacks Investment Research downgraded shares of Neovasc from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. ValuEngine downgraded shares of Neovasc from a “sell” rating to a “strong sell” rating in a research note on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Neovasc currently has an average rating of “Hold” and a consensus target price of $5.19.
Neovasc (NASDAQ NVCN) traded down $0.05 during trading on Friday, reaching $0.73. 365,389 shares of the company traded hands, compared to its average volume of 522,587. Neovasc has a 12-month low of $0.70 and a 12-month high of $3.34. The firm has a market cap of $61.56, a P/E ratio of 2.89 and a beta of 1.47.
Large investors have recently bought and sold shares of the business. Virtu KCG Holdings LLC acquired a new position in shares of Neovasc in the second quarter worth $149,000. Gagnon Advisors LLC lifted its position in shares of Neovasc by 0.5% during the 2nd quarter. Gagnon Advisors LLC now owns 1,212,850 shares of the medical equipment provider’s stock worth $1,674,000 after purchasing an additional 5,671 shares during the last quarter. Gagnon Securities LLC lifted its position in shares of Neovasc by 5.2% during the 2nd quarter. Gagnon Securities LLC now owns 3,023,087 shares of the medical equipment provider’s stock worth $4,172,000 after purchasing an additional 149,642 shares during the last quarter. Finally, Capital World Investors lifted its position in shares of Neovasc by 9.1% during the 2nd quarter. Capital World Investors now owns 6,294,667 shares of the medical equipment provider’s stock worth $8,737,000 after purchasing an additional 522,864 shares during the last quarter. Institutional investors and hedge funds own 19.22% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Neovasc Inc. (NASDAQ:NVCN) Forecasted to Post FY2017 Earnings of ($0.19) Per Share” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/12/04/fy2017-earnings-forecast-for-neovasc-inc-nvcn-issued-by-leerink-swann.html.
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Get a free copy of the Zacks research report on Neovasc (NVCN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.